Literature DB >> 7707514

Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.

A L Zaiman1, A F Lewis, B E Crute, N A Speck, J Lenz.   

Abstract

Core binding factor (CBF), also known as polyomavirus enhancer-binding protein 2 and SL3 enhancer factor 1, is a mammalian transcription factor that binds to an element termed the core within the enhancers of the murine leukemia virus family of retroviruses. The core elements of the SL3 virus are important genetic determinants of the ability of this virus to induce T-cell lymphomas and the transcriptional activity of the viral long terminal repeat in T lymphocytes. CBF consists of two subunits, a DNA binding subunit, CBF alpha, and a second subunit, CBF beta, that stimulates the DNA binding activity of CBF alpha. One of the genes that encodes a CBF alpha subunit is AML1, also called Cbf alpha 2. This locus is rearranged by chromosomal translocations in human myeloproliferative disorders and leukemias. An exogenously expressed Cbf alpha 2-encoded subunit (CBF alpha 2-451) stimulated transcription from the SL3 enhancer in P19 and HeLa cells. Activity was mediated through the core elements. Three different isoforms of CBF beta were also tested for transcriptional activity on the SL3 enhancer. The longest form, CBF beta-187, increased the transcriptional stimulation by CBF alpha 2-451 twofold in HeLa cells, although it had no effect in P19 cells. Transcriptional activation by CBF beta required binding to the CBF alpha subunit, as a form of CBF beta that lacked binding ability, CBF beta-148, failed to increase activity. These results indicated that at least in certain cell types, the maximum activity of CBF required both subunits. They also provided support for the hypothesis that CBF is a factor in T lymphocytes that is responsible for recognition of the SL3 cores. We also examined whether CBF could distinguish a 1-bp difference between the enhancer core of SL3 and the core of the nonleukemogenic virus, Akv. This difference strongly affects transcription in T cells and leukemogenicity of SL3. However, no combination of CBF alpha and CBF beta subunits that we tested was able to distinguish the 1-bp difference in transcription assays. Thus, a complete understanding of how T cells recognize the SL3 core remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707514      PMCID: PMC188987     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  How eukaryotic transcriptional activators work.

Authors:  M Ptashne
Journal:  Nature       Date:  1988-10-20       Impact factor: 49.962

2.  Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats.

Authors:  M K Short; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

3.  Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer.

Authors:  N A Speck; D Baltimore
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

4.  Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

5.  Cell-type specific expression of a transfected immunoglobulin gene.

Authors:  J Stafford; C Queen
Journal:  Nature       Date:  1983 Nov 3-9       Impact factor: 49.962

Review 6.  Enhancer elements.

Authors:  G Khoury; P Gruss
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

7.  Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.

Authors:  A L Boral; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

8.  Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat.

Authors:  J Lenz; D Celander; R L Crowther; R Patarca; D W Perkins; W A Haseltine
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers.

Authors:  S W Wang; N A Speck
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

View more
  30 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Long terminal repeat regions from exogenous but not endogenous feline leukemia viruses transactivate cellular gene expression.

Authors:  S K Ghosh; P Roy-Burman; D V Faller
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

Authors:  S Ethelberg; B D Tzschaschel; A Luz; S J Diaz-Cano; F S Pedersen; J Schmidt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

Authors:  Jennifer A Mertz; Ryuji Kobayashi; Jaquelin P Dudley
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Competitive binding of viral E2 protein and mammalian core-binding factor to transcriptional control sequences of human papillomavirus type 8 and bovine papillomavirus type 1.

Authors:  H M Schmidt; G Steger; H Pfister
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis.

Authors:  Leslie J Marshall; Amy C Moore; Misao Ohki; Issay Kitabayashi; David Patterson; David A Ornelles
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

8.  Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Authors:  Y Kanno; T Kanno; C Sakakura; S C Bae; Y Ito
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

9.  B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.

Authors:  J Lovmand; A B Sorensen; J Schmidt; M Ostergaard; A Luz; F S Pedersen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.

Authors:  M J Martiney; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.